SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes inspection of Lupin’s Pithampur facility

12 Feb 2020 Evaluate

United States Food and Drug Administration (USFDA) has completed inspection at Lupin’s Pithampur unit-1 facility. The inspection was carried out between February 3, 2020 and February 11, 2020. The inspection for the Pithampur unit-1 facility closed with two 483 observations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2457.45 -32.40 (-1.30%)
08-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1887.95
Dr. Reddys Labs. 1348.70
Cipla 1431.65
Zydus Lifesciences 1149.00
Lupin 2457.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: